恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并非酒精性脂肪肝的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Entecavir combined with Silybin in the treatment of chronic hepatitis B with non-alcoholic fatty liver disease. Methods A total of 120 patients with chronic hepatitis B and non-alcoholic fatty liver disease who treated in our hospital from January 2018 to September 2019 were selected as the research subjects and divided into the control group and the experimental group by random number table method, with 60 cases in each group. The control group was treated with Entecavir, and the experimental group was treated with Entecavir combined with Silybin. The liver function indexes (alanine aminotransferase [ALT], aspartate aminotransferase[AST], hepatitis B virus DNA [HBV-DNA]), the blood lipid indexs (total cholesterol [TC], triacylglycerol [TG], high density lipoprotein cholesterol [HDL-C], low density lipoprotein cholesterol [LDL-C]), abdominal B-ultrasound grading before and after treatment, clinical efficacy and adverse reactions of the two groups were compared. Results There were no statistically significant differences in the levels of ALT, AST and HBV-DNA between the two groups before treatment (P＞0.05). After treatment, the levels of ALT, AST and HBV-DNA in the experimental group were lower than those in the control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the levels of TC, TG, HDL-C and LDL-C between the two groups before treatment (P＞0.05). After treatment, the levels of TC, TG and LDL-C in the experimental group were lower than those in the control group, the level of HDL-C was higher than that in the control group, and the differences were statistically significant (P＜0.05).There was no statistically significant difference between the two groups in the abdominal B-ultrasound grading before treatment (P＞0.05). After treatment, the abdominal B-ultrasound grading in the experimental group was better than that in the control group, and the difference was statistically significant (P＜0.05). The total effective rate of the experimental group was higher than that of the control group, the total incidence of adverse reactions was lower than that of the control group, and the differences were statistically significant (P＜0.05). Conclusion The effect of Entecavir combined with Silybin in the treatment of patients with chronic hepatitis B and non-alcoholic fatty liver disease is more accurate. It can significantly improve the liver function indexs and blood lipid indexs of patients, improve the total effective rate of treatment, reduce the total incidence of adverse reactions, and it is worthy of clinical promotion and application.

Key words： Chronic hepatitis B Non-alcoholic fatty liver disease Entecavir Silybin Clinical curative effect

Received: 20 January 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/53

[5]	李丽萍，闻名，刘长明，等.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎患者疗效及其对肝功能、肝纤维化和炎性反应的影响[J].疑难病杂志，2019，18（3）：247-250.
[6]	李慧丽，李勇.恩替卡韦联合水飞蓟宾胶囊治疗慢性乙型肝炎合并非酒精性脂肪性肝炎临床观察[J].中西医结合肝病杂志，2019，29（5）：419-421.
[7]	王浩.瑞舒伐他汀联合恩替卡韦治疗慢性乙型肝炎伴脂肪肝的临床效果分析[J].中国地方病防治杂志，2017，32（7）：785-787.
[1]	龙云铸，李丹，谭英征，等.恩替卡韦联合水飞蓟宾葡甲胺片在乙肝相关性肝癌术后治疗的临床研究[J].新疆医科大学学报，2017，40（1）：35-37，41.
[2]	姚向波，尹毅，周筱燕.十味诃子汤散联合恩替卡韦治疗老年慢性乙型肝炎合并非酒精性脂肪肝的临床研究[J].现代中药研究与实践，2017，31（6）：72-76.
[3]	中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南（2018年更新版）[J].临床肝胆病杂志，2018，34（5）：947-957.
[4]	梁守赞，黄惠宜.恩替卡韦与水飞蓟宾胶囊联合治疗慢性乙型肝炎患者临床效果分析[J].实用肝脏病杂志，2018，21（2）：208-211.
[8]	林万宝，汤展展，杨玲.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎合并脂肪肝患者的效果分析[J].中国卫生工程学，2018，17（5）：787-789.
[9]	李旭.恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并NAFLD 患者疗效初步研究[J].实用肝脏病杂志，2017，20（6）：676-679.
[10]	臧彬.恩替卡韦联合水飞蓟宾葡甲胺治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者的临床疗效分析[J].当代医学，2018，24（29）：153-155.
[11]	孙燕燕，郭英，季伟.水飞蓟宾联合恩替卡韦治疗乙型病毒性肝炎肝硬化的疗效观察[J].中国医院用药评价与分析，2017，17（12）：1636-1637，1640.
[12]	蔡建刚，朱婷婷，刘芙蓉，等.水飞蓟宾联合恩替卡韦治疗乙型肝炎肝硬化的临床疗效[J].世界华人消化杂志，2016，24（12）：1898-1902.
[13]	张天.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎合并脂肪肝的疗效观察[J].现代消化及介入诊疗，2017，22（4）：492-494.
[14]	姜国生.恩替卡韦合水飞蓟宾治疗慢性乙型肝炎合并脂肪肝疗效观察[J].实用中西医结合临床，2019，19（5）：5-7.
[15]	赵波，戚永花，万强.恩替卡韦联合水飞蓟宾治疗慢性乙型肝炎并脂肪肝的临床疗效[J].临床合理用药杂志，2019，12（15）：23-25.